U.S., March 26 -- ClinicalTrials.gov registry received information related to the study (NCT07493512) titled 'Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer' on March 20.
Brief Summary: The primary objective of this trial is to determine the safety profile of xaluritamig at the proposed regimen in adult participants with metastatic castration-resistant prostate cancer (mCRPC).
Study Start Date: May 26
Study Type: INTERVENTIONAL
Condition:
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Intervention:
DRUG: Xaluritamig
Participants will receive xaluritamig via short-term intravenous (IV) infusion.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Amgen
Published by HT Digital Content Servi...